Src-bcr-Abl Src-bcr-Abl

Cat.No.	Name	Information
M2331	PP2	PP2 (AGL 1879) is a selective inhibitor of Src-family tyrosine kinases with >10,000-fold selectivity over ZAP-70 and JAK2.
M1701	Dasatinib	Dasatinib (BMS-354825) is a small molecule inhibitor of both the SRC and BCR/ABL tyrosine kinases, with IC50's for the isolated kinases of 0.55 and 3.0 nM, respectively.
M1648	AP24534	Ponatinib (AP24534) is a novel potent, orally available small molecule multitargeted kinase inhibitor of BCR-ABL, PDGFRα, c-Src, c-Kit, FGFR and VEGFR.
M1799	Imatinib Mesylate	Imatinib Mesylate is a Bcr-Abl tyrosine kinase inhibitor, with IC50 values of 2.9 and 3.9 μM for the inhibition of T-cell proliferation stimulated by PHA and DCs respectively.
M1685	Bosutinib	Bosutinib (SKI-606) is a novel Bcr-Abl inhibitor with IC50 values of 0.1 to 0.3 umol/L.
M3194	Nocodazole	Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM, respectively.
M1912	Nilotinib	Nilotinib (AMN107) is a small molecule Bcr-Abl kinase inhibitor with IC50 less than 30 nM.
M20833	Vodobatinib (K0706)	Vodobatinib (K0706, SCO-088, SUN K706, SUN-K0706) is a novel BCR-ABL1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants with IC50s of 167 nM, 154 nM,165 nM and 1967 nM for BCR-ABL1^L248R, BCR-ABL1^Y253H , BCR-ABL1^E255V and BCR-ABL1^T315I, respectively.
M20763	DGY-06-116	DGY-06-116 is an irreversible covalent and selective inhibitor of Src with IC50 of 2.6 nM.
M20633	TP0427736 HCl	TP0427736 is a potent inhibitor of ALK5 kinase activity with an IC50 of 2.72 nM and this effect is 300-fold higher than the inhibitory effect on ALK3 (IC50 = 836 nM for ALK3). It also inhibits Smad2/3 phosphorylation in A549 cells induced by TGF-β1 with an IC50 value of 8.68 nM.
M20580	HG-14-10-04	HG-14-10-04 is an inhibitor of ALK .
M20506	7-Hydroxy-4-chromone	7-Hydroxychromone is a Src kinase inhibitor with an IC50 of <300 μM.
M20466	Nilotinib hydrochloride	Nilotinib hydrochloride is the hydrochloride salt form of nilotinib, an orally bioavailable Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
M20137	WAY-329689	WAY-329689 has ABL kinase inhibiting activities.
M20136	WAY-329686	WAY-329686 has ABL kinase inhibiting activities.
M20135	WAY-329685	WAY-329685 has ABL kinase inhibiting activities.
M20128	WAY-329424	WAY-329424 has ABL kinase inhibiting activities.
M20127	WAY-329423	WAY-329423 has ABL kinase inhibiting activities.
M20126	WAY-329412	WAY-329412 has ABL kinase inhibiting activities.
M20125	WAY-329410	WAY-329410 has ABL kinase inhibiting activities.
M20124	WAY-329356	WAY-329356 has ABL kinase inhibiting activities.
M20123	WAY-329341	WAY-329341 has ABL kinase inhibiting activities.
M20122	WAY-329340	WAY-329340 has ABL kinase inhibiting activities.
M20121	WAY-328158	WAY-328158 is a Inhibitor for BCR-ABL Kinase.
M20022	GI-560708	GI-560708 is a inhibitor of BCR-ABL tyrosine kinase.
M14914	Src Inhibitor 3	Src Inhibitor 3 is a potent, orally active c-terminal Src kinase (CSK) with IC₅₀ values below 3 nM and 4 nM in CSK HTRF and Caliper assay, respectively.
M14909	1-Naphthyl PP1 hydrochloride	1-Naphthyl PP1 hydrochloride (1-NA-PP 1 hydrochloride) is a selective inhibitor of src family kinases. 1-Naphthyl PP1 hydrochloride inhibits v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with IC50s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively.

By Signaling Pathways

By Product Type

Signaling Pathways

Src-bcr-Abl Src-bcr-Abl

Get to Know Us

Customer Support

Resources

Contact Us